NAD+

NAD+ in 2026: Pathways, Precursors & SA Guide

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that powers redox reactions, sirtuin deacetylation, and PARP-driven DNA repair. Cells regenerate it through three biosynthesis routes: the de novo tryptophan pathway, the Preiss-Handler pathway (niacin), and the salvage pathway (NMN, NR, nicotinamide). Pathway efficiency declines with age, which is why precursor choice matters — different routes have different rate-limiting enzymes that respond differently to ageing.

In a 2024 Nature Metabolism head-to-head randomised controlled trial, oral NR and NMN roughly doubled whole-blood NAD+ after 14 days, while plain nicotinamide produced only a transient 4-hour spike. For South African researchers, that biochemistry now collides with practical questions: which precursor feeds which pathway, how SAHPRA treats NMN, NR, and IV NAD+ in 2026 — and where to source a batch-documented research-grade reference compound in ZAR, right now, without waiting. Order the Body Pharm NAD+ 1000 Pen on JCSG.org →

Key takeaways

• NAD+ biosynthesis declines with age because NAMPT (the rate-limiting salvage enzyme) loses activity and consumption by CD38 and PARP1 rises simultaneously.
• NR and NMN roughly double blood NAD+ within 14 days at 250–1,000 mg/day; nicotinamide produces only transient spikes.
• No randomised controlled trial has directly compared IV NAD+ to oral precursors on functional outcomes; IV evidence remains small case series.
• SAHPRA has not classified NMN or NR as medicines as of 2026, but injectable NAD+ requires Section 21 compounding oversight.
• Body Pharm NAD+ reference compounds on JCSG.org are batch-documented, priced in ZAR, and ready to order — view the product page now.

What is NAD+? A 2026 definition

NAD+ (nicotinamide adenine dinucleotide, oxidised form) is a coenzyme present in every living cell. It shuttles electrons in redox reactions, accepts a hydride to become NADH during catabolism, and is consumed by sirtuins, PARPs and CD38 as a substrate for signalling. The Cleveland Clinic's 26 February 2026 reference entry describes it as a coenzyme found in all living cells, essential for converting food into ATP because it accepts electrons during the breakdown of glucose and fats.

The NAD+/NADH couple drives the electron transport chain. Glycolysis, beta-oxidation and the Krebs cycle reduce NAD+ to NADH, which then donates electrons at Complex I to generate the proton gradient that powers ATP synthase. Without a steady cytosolic and mitochondrial NAD+ pool, ATP output falls and reductive biosynthesis stalls because the cell cannot complete the redox reactions needed for energy production and biosynthetic pathways.

South African researchers ready to source a batch-documented NAD+ reference compound today can order the Body Pharm NAD+ 1000 Pen on JCSG.org or browse our full peptide catalogue for related compounds. Current ZAR pricing is live in the buy box — no guesswork required.

NAD+ vs NADH vs NADP+: getting the forms right

The four NAD-family molecules differ on two axes: redox state (oxidised vs reduced) and phosphorylation. A 2′-phosphate on the adenine ribose distinguishes the NADP pool from the NAD pool because this single chemical modification routes the molecule into different metabolic pathways. NAD+ and NADH drive catabolism and ATP production. NADP+ and NADPH drive anabolism and antioxidant defence. The NAD+/NADH ratio is itself a readout of cellular metabolic state.

Why the NAD+/NADH ratio matters

A high cytosolic NAD+/NADH ratio signals an oxidised, fasted, energy-demanding state and licenses sirtuin activity because sirtuins require NAD+ as a substrate and are inhibited when the ratio drops. A low ratio signals reductive stress and stalls Krebs flux because the cell cannot accept more electrons from substrate oxidation. Precise clinical threshold values for healthy versus aged ratios in human tissue remain unverified in the 2024–2026 literature. Most reporting falls back on whole-blood NAD+ concentration as a practical proxy, which is measurable and correlates with tissue status in preliminary studies.

The three NAD+ biosynthesis pathways

Human cells build NAD+ through three routes: the de novo pathway from dietary tryptophan, the Preiss-Handler pathway from nicotinic acid (niacin), and the salvage pathway that recycles nicotinamide, NR, and NMN back into the pool. Salvage dominates in most mammalian tissues. The central story in age-related NAD+ loss is salvage-pathway enzyme decline because this pathway handles 80–90% of moment-to-moment NAD+ turnover in metabolic tissues.

De novo: tryptophan through kynurenine

The de novo route starts with dietary L-tryptophan and runs eight enzymatic steps through the kynurenine pathway to quinolinic acid. QPRT (quinolinate phosphoribosyltransferase) converts quinolinic acid to nicotinic acid mononucleotide (NaMN), which then funnels into the shared trunk that produces NAD+.

Flux through this pathway is low in most tissues outside the liver and kidney because QPRT expression is the rate-limiting bottleneck and is not highly expressed in muscle or adipose tissue. For a South African on a typical mixed diet — maize, chicken, eggs and pulses — de novo synthesis contributes a minor fraction of daily NAD+ turnover compared with salvage because the pathway is slow and tissue-restricted.

Preiss-Handler: niacin's direct on-ramp

Nicotinic acid (niacin, vitamin B3) enters via NAPRT (nicotinic acid phosphoribosyltransferase), which phosphoribosylates it to NaMN. NaMN is then adenylated by NMNAT1/2/3 to NaAD, and NAD synthetase amidates NaAD to NAD+.

NAPRT is the rate-limiting and feedback-resistant step. This is part of why pharmacological niacin doses raise NAD+ without the substrate inhibition seen with nicotinamide — NAPRT does not slow down when NAD+ levels rise. The trade-off is the well-known flushing response at gram-level doses, because niacin activates GPR109A on skin cells.

Salvage: the workhorse for NR, NMN and nicotinamide

The salvage pathway recycles nicotinamide (Nam) released by NAD+-consuming enzymes (sirtuins, PARPs and CD38) back into NAD+. NAMPT (nicotinamide phosphoribosyltransferase) converts Nam to NMN, then NMNAT enzymes adenylate NMN to NAD+. Exogenous NR enters one step earlier via NRK1/2 kinases, which phosphorylate NR to NMN before it joins the same NMNAT-catalysed step.

NAMPT is the rate-limiting enzyme of the whole salvage cycle, and its expression falls measurably with age because transcriptional regulation of NAMPT declines and protein stability decreases. That decline is the mechanistic basis for supplementing downstream intermediates rather than relying on endogenous recycling — bypassing the rate-limiting step can restore flux even when NAMPT is suppressed.

Mapping precursors to pathways: NMN, NR, niacin, tryptophan

Each precursor feeds a specific route:

• Tryptophan enters de novo synthesis via IDO/TDO, which catalyse the first committed step of the kynurenine pathway.
• Nicotinic acid (niacin) enters Preiss-Handler via NAPRT, the only enzyme that recognises niacin as a substrate.
• Nicotinamide, NR and NMN all feed the salvage pathway, differing only in how many enzymatic steps they skip before converging at NMNAT.

This pathway assignment dictates bioavailability, tissue distribution and which rate-limiting enzyme can bottleneck the response, because each pathway has different tissue expression patterns and enzymatic constraints.

NR enters salvage one step upstream of NMN, requiring NRK1/2 phosphorylation before adenylation. NMN is generally dephosphorylated to NR at the cell membrane by CD73 before re-entry, or transported intact via Slc12a8 in tissues that express it — this transporter is tissue-restricted.

The 2024 Nature Metabolism head-to-head randomised controlled trial by Cuenoud and colleagues found NR and NMN comparable in their ability to chronically increase baseline whole-blood NAD+ after 14 days, approximately doubling it. Equivalent nicotinamide produced only a transient 4-hour rise because nicotinamide is rapidly cleared and does not accumulate in tissues.

A 2026 practitioner review summarising parallel trials reports 2–3× NAD+ elevation with NR and 1.5–2.5× with NMN over similar windows, typically dosed at 250–1,000 mg/day.

Niacin bypasses NAMPT entirely via the feedback-resistant NAPRT step. This is why gram-level niacin still raises hepatic NAD+ where ageing-suppressed NAMPT limits salvage output. Tryptophan contributes only a minor share of daily NAD+ turnover in well-fed adults and is rarely used as a standalone precursor for research dosing because the de novo pathway is slow and requires high doses to achieve meaningful NAD+ elevation.

South African researchers comparing injectable references against oral precursor data can order the Body Pharm NAD+ 1000 Pen on JCSG.org or browse the full peptide catalogue for pathway-matched compounds. See current ZAR pricing live in the buy box — add to cart and ship today.

Why NAD+ declines with age

Tissue NAD+ falls with age because the salvage pathway loses throughput at the same time consumption ramps up. Covarrubias and colleagues (2021) documented this decline across liver, muscle, adipose and brain tissue, framing it as a supply-demand collapse rather than one broken enzyme because multiple mechanisms contribute simultaneously.

Falling NAMPT throttles the salvage pathway

NAMPT is the rate-limiting enzyme that recycles nicotinamide back into NMN, and its activity drops with age in metabolic tissues because NAMPT transcription declines and protein turnover increases. Because salvage handles the bulk of moment-to-moment NAD+ turnover, a sluggish NAMPT step starves the downstream NMNAT reaction even when precursor availability looks adequate on paper — the bottleneck is enzymatic capacity, not substrate.

This is the mechanistic reason niacin, which enters via NAPRT in the Preiss-Handler pathway, can still raise hepatic NAD+ in older tissue where NAMPT is suppressed: it bypasses the rate-limiting step entirely.

Rising CD38 consumes the pool

CD38 is one of the principal NAD+ hydrolases whose activity increases during ageing. Its expression climbs alongside chronic low-grade inflammation in adipose and immune cells because inflammatory signals upregulate CD38 transcription. A 2024 mechanistic review identifies CD38 inhibition with flavonoids (quercetin, apigenin, luteolin) or the small molecule 78c as a preclinical strategy that raises tissue NAD+ in mice. No large human outcome trials have landed yet because the field is still in early-stage development.

PARP activation from accumulated DNA damage

PARPs, particularly PARP1, cause massive NAD+ depletion during acute DNA damage responses because each DNA lesion repair event consumes multiple NAD+ molecules. Older tissue spends more time in PARP-active states because accumulated mutations and oxidative damage trigger more frequent repair. No 2024–2026 review fixes a precise PARP-versus-sirtuin consumption ratio in humans because the ratio varies by tissue and damage load. PARPs clearly out-consume sirtuins during damage episodes — a single DNA break can deplete local NAD+ pools faster than sirtuins can use it.

Net effect: sirtuin starvation. SIRT1, SIRT3 and SIRT6 share the same shrinking NAD+ pool that CD38 and PARP1 are draining faster because all three NAD+-consuming enzyme families compete for the same coenzyme.

NAD+, sirtuins and mitochondrial function

Sirtuins are a family of seven NAD+-dependent deacylases (SIRT1–SIRT7) that link cellular NAD+ status directly to gene silencing, DNA repair, and mitochondrial biogenesis. Each catalytic cycle consumes one NAD+ molecule per acetyl group removed, which is why sirtuin activity tracks the nuclear and mitochondrial NAD+ concentration rather than substrate availability alone — NAD+ is the rate-limiting cofactor.

The functional split across compartments matters for longevity biology. SIRT1 and SIRT6 work in the nucleus on histone and transcription-factor deacetylation, gating PGC-1α and FOXO programmes that drive mitochondrial turnover because these transcription factors activate genes encoding mitochondrial proteins. SIRT3, SIRT4 and SIRT5 sit inside the mitochondrial matrix. SIRT3 deacetylates components of the electron transport chain and antioxidant defences such as SOD2, which accumulate acetylation marks that reduce their activity.

When matrix NAD+ falls, SIRT3 output drops, and the resulting acetylation creep on respiratory complexes is a plausible contributor to the bioenergetic decline seen in aged tissue because acetylation reduces the catalytic efficiency of these enzymes.

Sharing a pool with PARP1

PARP1 and the sirtuins draw from the same NAD+ pool. During DNA damage responses PARP1 can deplete nuclear NAD+ rapidly enough to silence SIRT1 activity by substrate starvation because PARP1 consumes NAD+ faster than it can be resynthesised. No 2024–2026 review fixes a precise in vivo ratio for PARP-versus-sirtuin consumption in humans because the ratio depends on damage load and tissue type. Reviewers describe the flux as tissue- and context-dependent rather than a stable percentage.

The practical inference is that chronic genotoxic load, common in older or metabolically stressed tissue, biases the pool toward PARP1 and away from sirtuin-driven mitochondrial maintenance because PARP1 activation takes priority in DNA damage repair.

NAD+ precursor supplements: what the 2024–2025 evidence shows

Oral NMN and NR reliably raise blood NAD+ roughly two-fold over 14 days at doses in the 250–1,000 mg/day range. No human trial to date has demonstrated a longevity, lifespan or hard cognitive endpoint because such trials require decades of follow-up and are expensive to conduct.

The 2024 Cuenoud et al. trial in Nature Metabolism found NR and NMN comparable in their ability to chronically increase baseline whole-blood NAD+, while nicotinamide produced only a transient 4-hour spike because nicotinamide is rapidly cleared from circulation. A 2026 practitioner summary of a follow-up head-to-head reports 2–3× NAD+ increases with NR, 1.5–2.5× with NMN and 1.2–1.5× with high-dose nicotinamide over about two weeks. The underlying dose tables are not public because the studies are still under embargo or in press.

What the trials do not show is equally important. No published 2024–2026 randomised controlled trial directly compares IV NAD+ infusion to oral precursors in humans on longevity, cognitive, or metabolic endpoints. Existing IV studies remain small uncontrolled case series because the IV market is driven by clinic marketing rather than research funding. CD38 inhibition as an NAD+-sparing strategy is mechanistically attractive but still preclinical, with no large human outcome data as of 2024–2025.

Regulatory status for South African readers

The US FDA reclassified NMN as an investigational drug candidate in 2022, removing it from the legitimate dietary-supplement category in that market because the agency determined it required clinical development oversight. SAHPRA has not published NMN- or NR-specific guidance as of 2026, and neither precursor appears on current safety alerts or prohibited-substances lists because South Africa has not yet classified them as medicines. Verify scheduling directly with SAHPRA before importing or marketing because regulatory status can change.

Researchers benchmarking injectable formats against oral precursor data can order the Body Pharm NAD+ 1000 Pen on JCSG.org — current ZAR pricing is live in the buy box — or browse our full peptide catalogue when designing precursor-versus-injectable protocols.

NAD+ IV therapy: hype vs evidence in 2026

IV NAD+ delivers the molecule directly into plasma, bypassing gut absorption and the salvage-pathway conversion steps that oral NMN and NR depend on because the intravenous route avoids first-pass metabolism. That pharmacokinetic logic is real.

As of 2026, though, it does not translate into proven clinical superiority because no trial has measured functional outcomes. No randomised trial published between 2024 and 2026 has directly compared IV NAD+ infusion with oral precursors in humans on longevity, cognitive, or metabolic endpoints because such trials are expensive and require regulatory approval.

The current IV evidence base is mostly small uncontrolled case series and addiction-protocol reports, not the double-blind randomised controlled trial data that exists for oral NR and NMN at 250 to 1,000 mg/day. The IV market has simply grown faster than the research infrastructure. A 2026 clinician-facing guide on NAD therapy states plainly that no head-to-head randomised controlled trials comparing IV versus oral forms have yet established superiority.

What clinic marketing leaves out

South African longevity clinics charging premium per-session rates for “brain restoration” or anti-ageing drips lean on mechanism and testimonials rather than published outcome trials because no randomised controlled trial data supports the claims. SAHPRA treats injectable NAD+ as a medicine requiring registered manufacturing or Section 21 compounding oversight because it is administered parenterally and carries infection risk. That is a regulatory bar addressing safety and manufacturing standards, not a clinical efficacy endorsement.

For researchers wanting to benchmark injectable kinetics against oral data themselves, the Body Pharm NAD+ 1000 Pen on JCSG.org is the research-grade reference of choice — with batch CoA, ZAR pricing in the live buy box, and no clinic markup. Add to cart and order now. Weigh clinic marketing against the thin randomised controlled trial record before committing to expensive drip packages.

NAD+ research products in South Africa — order from JCSG.org

Sourcing NAD+ research compounds in South Africa in 2026 sits in a regulatory grey zone for oral forms. Oral NMN, NR and niacin are sold as health supplements without product-specific SAHPRA scheduling because SAHPRA has not yet classified them as medicines. Injectable NAD+, by contrast, is treated as a medicine requiring registered manufacture or Section 21 compounding because it is administered parenterally and requires pharmaceutical-grade quality assurance.

JCSG.org lists the Body Pharm NAD+ 1000 Pen as a research-grade reference compound, priced in ZAR with live pricing in the buy box — see the current price on JCSG.org (buy box above). No need to chase import quotes or wade through unverified supplement listings. Order directly on JCSG.org today →

The advertising rule that matters most: SAHPRA's complementary medicines framework classifies products by claimed indication. Any supplier promising to “treat”, “cure” or “reverse” fatigue, ageing or disease exposes themselves (and their customers) to enforcement risk because such claims reclassify the product as a medicine. Compliant copy describes molecular role and research use, not clinical outcomes.

What to check before buying — and why JCSG.org ticks every box

When evaluating a research-use supplier, the five-point checklist that matters — and how the Body Pharm NAD+ 1000 Pen on JCSG.org measures up:

• Certificate of Analysis (CoA) from an independent lab, matched to the batch number on the vial or pen. This proves the product was tested and links the result to your specific unit.
• Purity testing by HPLC (high-performance liquid chromatography) or LC-MS (liquid chromatography-mass spectrometry), with the chromatogram available on request. This shows the compound is free of synthesis byproducts and degradation products.
• Batch and lot traceability, so a specific unit can be linked to its synthesis and quality control run. This allows you to track any issues back to the manufacturing date.
• Honest labelling as for research use without therapeutic claims, consistent with SAHPRA's framework. This protects both you and the supplier from regulatory action.
• Cold-chain handling during courier delivery, with temperature logs where available. NAD+ precursors degrade at room temperature and lose potency if exposed to heat.

The Body Pharm NAD+ 1000 Pen on JCSG.org meets every point: batch-documented, independently tested, labelled for research use, ZAR-priced (see the current price on JCSG.org in the buy box), and shipped with cold-chain packaging. Verify the paperwork before the molecule — and order through our cart for fastest dispatch. You can also compare it against everything else in our full ZA peptide catalogue.

For research use only. Not for human consumption.

Frequently asked questions about NAD+

Is NAD+ a peptide?

No. NAD+ (nicotinamide adenine dinucleotide) is a dinucleotide coenzyme built from nicotinamide, ribose, and two phosphates linked to adenosine, not from amino acids — its backbone is a sugar-phosphate chain, not a polypeptide. JCSG.org lists the Body Pharm NAD+ 1000 Pen alongside peptides for research-market convenience because both are used in research protocols. Biochemically it is a nucleotide, not a protein.

Can you get NAD+ from food?

You get NAD+ precursors from food, not meaningful intact NAD+. Tryptophan (eggs, poultry), niacin and nicotinamide (meat, fish, fortified cereals), and trace NMN/NR (milk, edamame, avocado) feed the de novo, Preiss-Handler, and salvage pathways respectively. Dietary intake supports baseline NAD+ but rarely reaches the blood elevations seen with gram-scale supplementation because food portions are small and absorption is incomplete.

Is NMN legal in South Africa?

Yes, in practice. As of 2026, SAHPRA has issued no product-specific classification or safety alert for NMN or NR, and both are sold by local retailers as health supplements without a scheduling code. Disease-treatment claims, however, can reclassify a product as a medicine and trigger enforcement because SAHPRA's framework is indication-based.

How long until NAD+ supplements work?

Blood NAD+ rises within days. The 2024 Cuenoud et al. Nature Metabolism randomised controlled trial reported that oral NR and NMN roughly doubled whole-blood NAD+ within 14 days in healthy adults. Nicotinamide produced only a transient 4-hour spike because it is rapidly cleared. Tissue-level effects and any functional readouts take longer and remain less well characterised because tissue NAD+ kinetics differ from blood kinetics and functional endpoints require weeks to months to manifest.

What is the difference between NAD+ and NADH?

NAD+ is the oxidised form. NADH is the reduced form carrying two electrons and a proton because the reduction reaction adds a hydride ion (H−) to the nicotinamide ring. The pair shuttles electrons through glycolysis, the TCA cycle, and oxidative phosphorylation — NAD+ accepts electrons and NADH donates them.

The NAD+/NADH ratio, not absolute NAD+, governs sirtuin activity and redox-sensitive signalling because sirtuins sense the redox state, not the total pool size. Bulk supplementation does not automatically shift the ratio, which is why blood NAD+ elevation and functional benefit are not the same thing.

Are NAD+ side effects documented?

Yes, mild ones. Across 2024–2025 oral NMN and NR trials at 250 to 1,000 mg/day, reported events include flushing (mainly with niacin), nausea, and headache. No serious adverse signals have emerged in short-term studies because these doses are well tolerated in healthy adults. IV NAD+ side effects (chest pressure, nausea during infusion) are described in clinical reports but lack randomised controlled trial-grade data because IV studies are small and uncontrolled.

Order NAD+ research compounds in South Africa today

Ready to source a batch-documented, independently tested NAD+ reference compound in ZAR? Don't wait. Order the Body Pharm NAD+ 1000 Pen on JCSG.org now → See the current ZAR price live in the buy box, request the batch CoA, and check it against the precursor options across our full ZA peptide catalogue. Verify SAHPRA scheduling for your specific use case, document everything against the five-point checklist above, and add to cart for same-business-day dispatch.

For pricing context on the broader South African market, you can also see what's available at beskinny.store — though for Body Pharm NAD+ with batch documentation and ZAR checkout, JCSG.org is where you order.